---
company: Enovix Corp
ticker: ENVX
form: 8-K
filed: 2026-05-13
accession: 0001828318-26-000027
source: https://www.sec.gov/Archives/edgar/data/1828318/000182831826000027/
---

# Enovix (ENVX) earnings release, May 13, 2026

Enovix Corp (ENVX) · Form 8-K, Item 2.02 · Filed 2026-05-13 · [SEC filing](https://www.sec.gov/Archives/edgar/data/1828318/000182831826000027/)

Enovix Reports First Quarter 2026 Results

Enovix Begins Commercial Production of Silicon-Anode Smart Eyewear Battery

Enovix Advances Toward Smartphone Qualification Completion

FREMONT, Calif., May 13, 2026 -- Enovix Corporation (Nasdaq: ENVX) (“Enovix”), a developer and manufacturer of advanced lithium-ion batteries, including proprietary silicon-anode architectures, today reported financial results for the first quarter of 2026. The Company will host a live webcast at

5:00 PM ET / 2:00 PM PT to discuss the results and provide a business update. To register for the webcast, please visit: https://enovix-q1-2026.open-exchange.net/.

Commercialization Progress

“Smartphones remain our priority as we advance toward completing qualification with our lead customer and prepare for commercial production for the most demanding market in consumer electronics,” said Dr. Raj Talluri, President and CEO of Enovix. “We aligned with our lead smartphone customer on a silicon-specific qualification framework — a significant step forward in completing this process. Our second smartphone OEM customer has also acknowledged that the legacy 0.7C cycle-life test is not appropriate for silicon batteries. We are discussing a replacement qualification framework expected to be consistent with the one adopted by our lead customer. We believe this addresses the primary structural barrier to qualification of our 100% silicon anode batteries and reinforces the broader applicability across the smartphone market. Based upon results to date, we continue to see encouraging performance trends across energy density, fast charge, and safety metrics, while cycle-life testing under these enhanced protocols remains ongoing. We recognize this qualification process has taken longer than we originally anticipated — these updated frameworks represent the clearest path to completing it. Beyond smartphones, our defense business continues to generate strong commercial momentum. In addition, our smart eyewear battery is entering early production.”

Cycle-life testing is now progressing under these updated evaluation frameworks, with results approaching performance thresholds. These frameworks extend testing duration while providing improved visibility into real-world performance across multiple operating conditions. Final qualification timing will depend on completion of testing and customer validation processes. These updated protocols increase testing rigor and duration rather than reduce qualification requirements. The Company is also continuously advancing its core battery platform, expected to deliver further cycle-life improvements and represent additional product qualification pathways. This supports our expectation for a targeted system-level deployment in the second half of 2026 with a lead smartphone OEM to confirm in-field performance ahead of broader commercial introduction. Simultaneously, we are in collaboration with our lead customer on the battery form factor for next year’s product launch.

Customer engagement continues to expand across AI-powered applications requiring high energy density in compact form factors. In smart eyewear, Enovix has begun initial shipments and expects to ramp manufacturing in the third quarter to support a leading smart eyewear reference platform. We expect to produce approximately 50,000 units in 2026 and increase into 2027 as downstream deployments expand. We believe this represents an important initial validation that our 100% silicon-anode architecture can be manufactured at commercial scale.¹

In parallel, Enovix sees growing demand across drone, defense, and industrial applications, securing new customer design wins during Q1 2026 in each of these markets with deployments expected in 2027. The Company’s global pipeline for products manufactured in Korea now exceeds $130 million, with the majority driven by rapidly expanding drone applications, where demand for high-performance battery solutions continues to outpace available supply and creates opportunity for an additional scaled, high-performance supplier. We believe Enovix is positioned to emerge as that differentiated supplier in this rapidly expanding market.

MX-1™ Drone Product Launch

To further support growth in these markets, Enovix is launching MX-1 — short for Mission Execution — a platform designed for applications requiring rugged design, rapid discharge, and high gravimetric energy density. MX-1 is the Company's first silicon-enhanced product line, developed by its integrated R&D and operations teams, and manufactured in our South Korea factory. MX-1 builds on a proven graphite-anode architecture, already deployed with leading South Korean defense contractors. The first MX-1 platform product — MX1-B01 drone cell — with 360 Wh/kg energy density and extended cycle life, positioning Enovix competitively with leading high-performance battery suppliers. Looking ahead, our next generation product is targeted for 2027 with a goal of reaching 400 Wh/kg.

Technology Progress

Enovix produced its first AI-2 engineering samples this quarter, a next-generation smart eyewear battery expected to deliver more than 20% higher volumetric energy density than AI-1. AI-2 leverages the EX-3M technology node, which reduces separator and current collector thickness, improves packaging efficiency, and increases cathode voltage. Customer sampling is planned for later in the second quarter of 2026. The same EX-3M innovations are also expected to support a step-function in performance gains for Enovix's future smartphone batteries.

Manufacturing Readiness Progress... (truncated)g. This approach allows Enovix to apply the most effective technique at each step and is expected to increase production rates and support early commercial demand as qualification progresses.

Leadership

As previously announced, Enovix recently appointed Steve Bakos as Senior Vice President of Worldwide Sales to help drive its next phase of commercial expansion. Bakos brings more than 35 years of global semiconductor sales leadership, most recently serving as Vice President of Corporate Account Sales at Infineon Technologies. Earlier in his career, he held senior sales, distribution and marketing leadership roles at Linear Technology, Intersil, and Exar. His appointment reflects expanding market opportunities and Enovix’s commitment to building the commercial infrastructure needed for scaled revenue growth.²

First Quarter 2026 Financial Results

(in millions, except percentages)

• First quarter 2026 revenue of $7.6 million exceeded the high end of the Company’s guidance range and increased 49% year-over-year, primarily reflecting continued strength in defense and industrial shipments. Cells manufactured through Enovix’s South Korea operations continue deployment across defense applications, including aerial drones, subsea systems and munitions platforms, while next-generation silicon-anode developments position Enovix to support future higher-performance applications. Operational experience from these programs continues to inform manufacturing improvements as Enovix prepares for commercial-scale battery production. Revenue growth this quarter reflects increasing traction in markets capable of supporting broader scale over time.

• GAAP gross profit was $1.6 million and non-GAAP gross profit was $2.0 million in 1Q26. Non-GAAP gross margin improved to 26.3%, reflecting improved production volumes and continued progress in manufacturing execution, marking the sixth consecutive quarter of positive gross profit on both a GAAP and non-GAAP basis. This marks a continued progression toward economically scalable production.

• Net cash used in operating activities of $33.1 million in 1Q26, compared to an outflow of $16.9 million in 1Q25. Free cash flow was an outflow of $36.3 million in 1Q26, compared to an outflow of $23.2 million in 1Q25 primarily reflecting changes in working capital, the timing of capital expenditures, continued investment in manufacturing scale-up, and higher interest expense associated with the semi-annual interest payment of the Company’s convertible notes issued in the third quarter of 2025.

• Cash, cash equivalents and marketable securities totaled approximately $582.7 million at quarter-end, providing liquidity to support qualification completion and commercialization scale-up. Enovix continues to prioritize disciplined capital allocation as it advances manufacturing scale-up and commercialization, while maintaining flexibility to pursue select strategic opportunities. No shares were repurchased during the quarter under the Company’s previously authorized share repurchase program. The Company continues evaluating disciplined capital deployment alternatives under its existing authorization.³

First Quarter 2026 Financial Summary

(unaudited, in millions, except per share data and percentages)

(1) Net loss per share attributable to Enovix (2) Weighted average shares attributable to Enovix⁴

Chairman’s First Quarter 2026 Summary

Every quarter just prior to the board meeting, I attend a six‑hour meeting directly with Enovix “techies” to get updated on R&D and our new Malaysian factory, so that I can write a relevant report addressing investor feedback and concerns.

The Enovix battery is the single most difficult project I’ve ever worked on, beginning in 2012 when I joined Enovix as an investor and board member. In those private‑company days, the “board meetings” were mostly used to review the latest experiments. The original Enovix founders recruited me to invest partly because my PhD thesis was about using hydrazine (literally rocket fuel), which etches silicon strictly along crystal planes, to create nearly perfect grooves in silicon wafers on which I made transistors and simple Integrated Circuit (IC) chips at the Stanford IC laboratory, a world‑class center of excellence on “Moore’s Law.” Enovix had used the same technique to make lithium‑ion batteries inside grooves in silicon wafers. I agreed to join Enovix with the logic of “how hard could it be to make a battery with five‑micron geometries inside the grooves in a silicon wafer where I had already made sub‑micron transistors?” The answer is 14 years hard and counting.

The lithium atom is 0.15 nanometers in diameter, or 3,700 times smaller than a wavelength of green light. It is arguably the sharpest knife in the world, which easily slices between the layers of silicon atoms in a wafer, turning a once‑sturdy crystal into “mush” after just 10 battery charge‑discharge cycles. We never got the battery‑in‑silicon to work. When the founders of Enovix were down to their last $200,000 of venture money, they postulated that they could stack normal battery materials, the anode layer (silicon on copper foil) and cathode layer (cobalt oxide on aluminum foil) to create the same effective structure as they had on silicon wafers. I literally advised, “Do your last silicon wafer experiment and die like men,” but they were right and made the new structure work on the first try, convincing investors, including me, to continue to support them. Today, we routinely achieve a 500‑cycle life, same as the 500‑cycle standard in place for years, but not yet the 800‑cycle level needed for today’s smart phones.... (truncated)one yielded above 80%. Today, all but two steps yield above 90% with the other two at approximately 80% and 88%. I now believe our new battery line is going to work with good yield, but I warn that, as in Moore’s Law for silicon, bringing on an all‑new manufacturing line is a two‑year journey that we are only halfway through. Today, despite making thousands of batteries, the line does not run fast enough due to the slow speed of laser cutting the hard cobalt oxide cathode. We have decided not to buy the additional (approximately $1 million each) lasers required to achieve 1,350 uph, based on economics. Meanwhile, we have been working for over a year on standard die cutting technology to replace laser cutting, and are now able to make thousands of batteries per quarter while we work on line speed.

My focus is now back on R&D – getting the battery cycle life up to 800 cycles. Meanwhile, we are sampling production‑worthy batteries for smart eyewear, a market in which we continue to have a leading product that does meet the required specs. The good news is that our smart eyewear batteries use 12 times less raw material than a cellphone battery, and thus run faster with higher yield through our line. We have already shipped smart eyewear sample batteries to 15 customers and expect to ship 50,000 samples and prototypes in 2026.

After 14 years, it would be foolish to project quick success, but we are without a doubt moving consistently in the right direction.⁵

Financial Outlook

(unaudited, in millions, except per share data)

(1)

Our outlook does not include provisions for proposed tax law changes or for the recently enacted tax reform legislation, future asset impairments or for pending legal matters, other than future legal amounts that are probable and estimable. Further, due to their nature, certain income and expense items, such as certain investments, derivative and foreign currency transaction gains or losses, cannot be accurately forecast. Accordingly, we only include such items in our financial outlook to the extent they are reasonably certain. Actual results may differ materially from the outlook; (2) See Appendix for definitions and reconciliations of non-GAAP Gross Profit (Loss), non-GAAP Gross Margin, non-GAAP Operating Loss, Adjusted EBITDA, and non-GAAP Net Loss Per Share Attributable to Enovix to their nearest comparable GAAP metrics; (3) non-GAAP Net Loss represents non-GAAP Net Loss Per Share Attributable to Enovix; (4) Capital Expenditures reflects cash paid for property, equipment, and manufacturing assets and is a component of our free cash flow calculation. It excludes depreciation, accretion, amortization, and other non-cash investing items. It excludes one-time cash outflows related to business acquisitions.

About Enovix

Enovix develops and manufactures advanced lithium-ion batteries, including proprietary silicon-anode architectures for smartphones, smart eyewear, defense, industrial and emerging edge-AI applications. Its proprietary silicon-anode battery architecture enables higher energy density and performance in space-constrained devices while maintaining safety and reliability, supporting commercialization across consumer and industrial markets.

Enovix is headquartered in Silicon Valley with facilities in India, Korea and Malaysia, servicing customers globally. For more information visit https://enovix.com and follow us on

LinkedIn.

Non-GAAP Financial Measures

This press release includes the use of non-GAAP financial measures, which are intended to provide supplemental information regarding our performance. These non-GAAP measures include non-GAAP cost of revenue, non-GAAP gross profit (loss), non-GAAP gross margin, non-GAAP research and development expense, non-GAAP selling, general and administrative expense, non-GAAP operating expenses, non-GAAP income (loss) from operations, EBITDA, adjusted EBITDA, non-GAAP net loss attributable to Enovix shareholders, non-GAAP earnings (loss) per share, free cash flow, and other non-GAAP measures that are included in this press release.

We use these non-GAAP measures to supplement our financial reporting and to evaluate ongoing operations and results, facilitate internal planning and forecasting, and assess performance against prior periods, industry peers, and the broader market. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles (GAAP) and should not be considered as an alternative to GAAP results. Industry peers and other companies may calculate similar non-GAAP measures differently. Non-GAAP financial measures have limitations, including but not limited to, that they exclude certain expenses that are required under GAAP, which adjustments reflect the exercise of judgment by management. We believe that these non-GAAP measures, when considered together with the GAAP results, provide investors with an additional understanding of our operating performance. Reconciliations of each non-GAAP financial measure to the most directly comparable GAAP financial measure can be found in the tables at the end of this press release.

While Enovix provides second quarter 2026 guidance for non-GAAP loss from operations, non-GAAP net loss per share and capital expenditures, we are unable to provide without unreasonable effort a GAAP to non-GAAP reconciliation of these projected non-GAAP measures, and we have not provided a quantitative reconciliation in⁶... (truncated) costs related to shareholder lawsuit, gain on bargain purchase of assets, acquisition-related costs, and restructuring costs. As a result, we are unable to assess the probable significance of the unavailable information, which could have a material impact on our future GAAP financial results.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events or our future financial or operating performance and are identified by words such as anticipate, believe, could, estimate, expect, intend, may, might, plan, possible, potential, predict, project, should, will, would and similar expressions.

Forward-looking statements in this press release include, but are not limited to, statements regarding: our future operating results, financial position, growth opportunities and guidance; expected performance, capabilities and advantages of our battery products, including projected improvements in energy density, cycle life, future product development and technology roadmap; the status, timing and scale of our launch of various customer programs in 2026 and beyond; our expectations regarding alignment and timing, results and impact of customer testing and qualification requirements; our ability to meet required performance thresholds and progress toward commercial deployment; our ability to build, scale and optimize manufacturing lines for our advanced silicon-anode lithium-ion batteries, including improvements in yield, throughput, dicing processes, performance, cost efficiency and overall production economics; our ability to execute on our commercialization strategy and transition to high-volume production, including the timing of sampling, product launches, production ramps and system-level deployment; estimates relating to total addressable markets, customer demand and the suitability of our batteries for next-generation applications, including smartphones, smart eyewear, IoT, defense and industrial markets; our ability to maintain technological and performance advantages over competing battery technologies and architectures; our expectations regarding our AI and MX platforms and the demand for greater energy density in our intended markets, the suitability of our batteries to address this demand, and the impact of artificial intelligence (AI) on the foregoing; our ability to align with, retain and expand relationships with top-tier OEMs and other customers, grow our customer pipeline, convert commercial opportunities into revenue and achieve scaled revenue growth; the sufficiency of our capital resources and our expectations regarding the benefits and use of our current balances of cash, cash equivalents and marketable securities; and our ability to raise additional capital through equity, debt or other financing arrangements to support operations, growth initiatives and capital expenditures.

It is not possible for us to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. Accordingly, you should not rely on any of the forward-looking statements. For additional information on these risks and uncertainties and other potential factors that could cause actual results to differ from the results predicted, please refer to our filings with the Securities and Exchange Commission (“SEC”), including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our annual report on Form 10-K and quarterly reports on Form 10-Q and other documents that we have filed, or will file, with the SEC. These documents are available in the SEC Filings section of the Investor Relations page at https://ir.enovix.com and at www.sec.gov.⁷

Any forward-looking statements in this press release speak only as of the date on which they are made. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

For media and investor inquiries, please contact:

Investor Contact: Chief Financial Officer:

Robert Lahey Ryan Benton ir@enovix.com ryan.benton@enovix.com⁸

## Financial statements

### Income Statement ((unaudited, in millions, except per share data and percentages))

| | GAAP – Q1 2026 | GAAP – Q1 2025 | GAAP – YoY Δ | Non-GAAP – Q1 2026 | Non-GAAP – Q1 2025 | Non-GAAP – YoY Δ |
|---|---:|---:|---:|---:|---:|---:|
| Revenue | 7.6 | 5.1 | 2.5 | 7.6 | 5.1 | 2.5 |
| Gross profit | 1.6 | 0.3 | 1.3 | 2 | 0.4 | 1.6 |
| Gross margin | 20.4 | 5.1 | 15pts | 26.3 | 7.5 | 19pts |
| Operating expenses | 45.4 | 42.8 | 2.6 | 30.8 | 28.3 | -2.5 |
| Loss from operations | -43.9 | -42.6 | -1.3 | -28.8 | -28 | -0.8 |
| Change in operating assets and liabilities | -9.2 | 1.5 | -10.7 | -9.2 | 1.5 | -10.7 |
| Net cash used in operating activities | -33.1 | -16.9 | -16.2 | -33.1 | -16.9 | -16.2 |
| Free cash flow | N/A | N/A | N/A | -36.3 | -23.2 | -13.1 |
| Adjusted EBITDA | N/A | N/A | N/A | -20.3 | -20.8 | 0.5 |
| Net loss per share, basic (1) | -0.18 | -0.12 | -0.06 | -0.14 | -0.13 | -0.01 |
| Weighted average shares, basic (2) | 217.4 | 203.3 | 14.1 | 217.4 | 203.3 | 14.1 |
| Net loss per share, diluted (1) | -0.18 | -0.12 | -0.06 | -0.14 | -0.13 | -0.01 |
| Weighted average shares, diluted(2) | 217.4 | 203.3 | 14.1 | 217.4 | 203.3 | 14.1 |

### Income Statement (Q2 2026 Guidance(1) — (unaudited, in millions, except per share data))

| | Q2 2026 Guidance(1) | Q2 2025 Results | Q1 2026 Results |
|---|---:|---:|---:|
| Revenue | $8.0 - 9.0 | 7.5 | 7.6 |
| Non-GAAP loss from operations (2) | ($29.0 - 32.0) | -26.5 | -28.8 |
| Non-GAAP net loss per share (2),(3) | ($0.13 - 0.17) | -0.13 | -0.14 |
| Capital expenditures (4) | $9.0 - 13.0 | 8 | 3.2 |

### Income Statement (Fiscal Quarters Ended — (Unaudited, in thousands, Except Share and per Share Amounts))

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| Revenue | 7,600 | 5,098 |
| Cost of revenue | 6,048 | 4,837 |
| Gross profit | 1,552 | 261 |
| Operating expenses: | Research and development | 26,528 | 25,929 |
| Operating expenses: | Selling, general and administrative | 18,919 | 16,892 |
| Operating expenses: | Total operating expenses | 45,447 | 42,821 |
| Operating expenses: | Loss from operations | -43,895 | -42,560 |
| Other income (expense): | Change in fair value of common stock warrants | 6,397 | 15,796 |
| Other income (expense): | Interest income | 5,776 | 2,434 |
| Other income (expense): | Interest expense | -7,008 | -1,716 |
| Other income (expense): | Other income, net | 343 | 2,353 |
| Other income (expense): | Total other income (expense), net | 5,508 | 18,867 |
| Other income (expense): | Loss before income tax benefit | -38,387 | -23,693 |
| Other income (expense): | Income tax benefit | -129 | -162 |
| Other income (expense): | Net loss | -38,258 | -23,531 |
| Other income (expense): | Net gain (loss) attributable to non-controlling interest | 2 | -21 |
| Other income (expense): | Net loss attributable to Enovix | -38,260 | -23,510 |
| Other income (expense): | Net loss per share attributable to Enovix shareholders, basic and diluted (1) | -0.18 | -0.12 |
| Other income (expense): | Weighted average number of common shares outstanding, basic and diluted (1) | 217,371,926 | 203,328,890 |

### Income Statement (Fiscal Quarters Ended)

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| Net loss attributable to Enovix | -38,260 | -23,510 |
| Interest expense (income), net | 1,232 | -718 |
| Income tax benefit | -129 | -162 |
| Depreciation, accretion and amortization | 9,370 | 8,448 |
| EBITDA | -27,787 | -15,942 |
| Stock-based compensation expense | 11,765 | 12,014 |
| Change in fair value of common stock warrants | -6,397 | -15,796 |
| Legal cost related to shareholder lawsuit (1) | 2,076 | 1,404 |
| Import duty forgiveness |  | -2,431 |
| Adjusted EBITDA | -20,343 | -20,751 |

### Income Statement (Fiscal Quarters Ended — These non-GAAP measures may differ from similarly titled measures used by other companies.)

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| GAAP loss from operations | -43,895 | -42,560 |
| Stock-based compensation expense | 11,765 | 12,014 |
| Amortization of intangible assets | 1,281 | 1,190 |
| Legal cost related to shareholder lawsuit (1) | 2,076 | 1,404 |
| Non-GAAP loss from operations | -28,773 | -27,952 |
| Depreciation, accretion and amortization (excluding amortization of intangible assets) | 8,089 | 7,258 |
| Other income (loss), net (excluding import duty forgiveness) | 343 | -78 |
| Net gain (loss) attributable to non-controlling interest | -2 | 21 |
| Adjusted EBITDA | -20,343 | -20,751 |

### Income Statement (Fiscal Quarters Ended — These non-GAAP measures may differ from similarly titled measures used by other companies.)

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| Revenue | 7,600 | 5,098 |
| GAAP cost of revenue | 6,048 | 4,837 |
| Stock-based compensation expense | -445 | -121 |
| Non-GAAP cost of revenue | 5,603 | 4,716 |
| GAAP gross profit | 1,552 | 261 |
| Stock-based compensation expense | 445 | 121 |
| Non-GAAP gross profit | 1,997 | 382 |
| GAAP research and development (R&D) expense | 26,528 | 25,929 |
| Stock-based compensation expense | -5,070 | -6,355 |
| Amortization of intangible assets | -448 | -416 |
| Non-GAAP R&D expense | 21,010 | 19,158 |
| GAAP selling, general and administrative (SG&A) expense | 18,919 | 16,892 |
| Stock-based compensation expense | -6,250 | -5,538 |
| Amortization of intangible assets | -833 | -774 |
| Legal cost related to shareholder lawsuit (1) | -2,076 | -1,404 |
| Non-GAAP SG&A expense | 9,760 | 9,176 |
| GAAP operating expenses | 45,447 | 42,821 |
| Stock-based compensation expense included in R&D expense | -5,070 | -6,355 |
| Stock-based compensation expense included in SG&A expense | -6,250 | -5,538 |
| Amortization of intangible assets | -1,281 | -1,190 |
| Legal cost related to shareholder lawsuit (1) | -2,076 | -1,404 |
| Non-GAAP operating expenses | 30,770 | 28,334 |

### Balance Sheet ((Unaudited, in thousands, except share and par value amounts))

| | As of April 5, 2026 | As of December 28, 2025 |
|---|---:|---:|
| Current assets: | Cash and cash equivalents | 88,751 | 106,014 |
| Current assets: | Short-term investments | 439,985 | 406,026 |
| Current assets: | Accounts receivable, net | 3,943 | 4,421 |

### Cash Flow (Fiscal Quarters Ended — (Unaudited, in thousands))

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| Cash flows used in operating activities: | Net loss | -38,258 | -23,531 |
| Adjustments to reconcile net loss to net cash used in operating activities | Depreciation, accretion and amortization | 9,370 | 8,448 |
| Adjustments to reconcile net loss to net cash used in operating activities | Stock-based compensation expense | 11,765 | 12,014 |
| Adjustments to reconcile net loss to net cash used in operating activities | Change in fair value of common stock warrants | -6,397 | -15,796 |
| Adjustments to reconcile net loss to net cash used in operating activities | Others | -386 | 479 |
| Changes in operating assets and liabilities: | Accounts and notes receivables | 4,359 | 430 |
| Changes in operating assets and liabilities: | Inventory | -2,834 | -2,826 |
| Changes in operating assets and liabilities: | Prepaid expenses and other assets | -1,252 | 2,440 |
| Changes in operating assets and liabilities: | Accounts payable | -3,600 | 4,420 |
| Changes in operating assets and liabilities: | Accrued expenses and compensation | -4,058 | -4,167 |
| Changes in operating assets and liabilities: | Deferred revenue | -736 | -457 |
| Changes in operating assets and liabilities: | Deferred tax liability | -241 | -33 |
| Changes in operating assets and liabilities: | Other liabilities | -804 | 1,672 |
| Changes in operating assets and liabilities: | Net cash used in operating activities | -33,072 | -16,907 |
| Cash flows from investing activities: | Purchase of property and equipment | -3,220 | -6,272 |
| Cash flows from investing activities: | Payment for business acquisition |  | -16 |
| Cash flows from investing activities: | Purchases of investments | -103,458 | -58,083 |
| Cash flows from investing activities: | Maturities of investments | 125,008 |  |
| Cash flows from investing activities: | Net cash provided by (used in) investing activities | 18,330 | -64,371 |
| Cash flows from financing activities: | Payroll tax payments for shares withheld upon vesting of RSUs | -1,663 | -1,761 |
| Cash flows from financing activities: | Purchase of Routejade shares from non-controlling interest | -740 |  |
| Cash flows from financing activities: | Repayment of debt | -55 |  |
| Cash flows from financing activities: | Proceeds from the exercise of stock options |  | 782 |
| Cash flows from financing activities: | Payments of transaction costs related to common stock issuance |  | -512 |
| Cash flows from financing activities: | Net cash used in financing activities | -2,458 | -1,491 |
| Cash flows from financing activities: | Effect of exchange rate changes on cash, cash equivalents and restricted cash | -147 | -228 |
| Cash flows from financing activities: | Change in cash, cash equivalents, and restricted cash | -17,347 | -82,997 |
| Cash flows from financing activities: | Cash and cash equivalents and restricted cash, beginning of period | 107,979 | 274,691 |
| Cash flows from financing activities: | Cash and cash equivalents and restricted cash, end of period | 90,632 | 191,694 |

### Cash Flow (Fiscal Quarters Ended)

| | Fiscal Quarters Ended – April 5, 2026 | Fiscal Quarters Ended – March 30, 2025 |
|---|---:|---:|
| Net cash used in operating activities | -33,072 | -16,907 |
| Capital expenditures | -3,220 | -6,272 |
| Free cash flow | -36,292 | -23,179 |
